RayKnowChina Research Map
Shortlist

Huai'anNanjing Medical University

Huai'an First People's Hospital

淮安市第一人民医院

Listed for 15 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Huai'an First People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌1 paper led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌20 papers led
  3. Hepatocellular carcinoma肝细胞癌6 papers led
  4. Stomach cancer胃癌13 papers led
  5. Lung cancer肺癌19 papers led
  6. Glioma胶质瘤5 papers led
  7. Hepatoblastoma肝母细胞瘤0 papers led
  8. Retinoblastoma视网膜母细胞瘤3 papers led
  9. Osteosarcoma骨肉瘤6 papers led
  10. Gastrointestinal stromal tumour胃肠道间质瘤3 papers led
  11. Neuroblastoma神经母细胞瘤1 paper led
  12. Multiple myeloma多发性骨髓瘤6 papers led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
  14. Lymphoma淋巴瘤11 papers led1 open trial led
  15. Coronary heart disease冠心病5 papers led

Not listed for: Pancreatic cancer, Breast cancer, Chordoma, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 1 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Huai'an for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 20 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
20
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 0020222023: 2220232024: 6620242025: 882025

2 hospitals in Huai'an for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImaging & AISurgery
Departments in papersRadiology / nuclear medicineRadiation oncologyMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led20
  1. Paclitaxel/Luteolin Coloaded Dual-Functional Liposomes for Esophageal Cancer Therapy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Chemoradiotherapy with or Without Anlotinib for Postoperative Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma: A Real-World Observational Study.2025Drug design, development and therapyFree full text
  3. Prognostic value of the ARISCAT score for postoperative pneumonia in patients with esophageal squamous cell carcinoma: a retrospective cohort study.2025European journal of medical researchFree full text
  4. HPGD induces ferroptosis and autophagy to suppress esophageal squamous cell carcinoma through the LXA4-ERK1/2-U2AF2-TFRC axis.2025Molecular cancerFree full text
  5. Impact of Dietary Behavioural Changes on Prognosis of Postoperative Oesophageal Squamous Cell Carcinoma Patients: A Retrospective Cohort Study.2025Nursing openFree full text
  6. CT-radiomics combined with inflammatory indicators for prediction of progression free survival of resectable esophageal squamous cell carcinoma.2025Scientific reportsFree full text
  7. Predicting the Efficacy of Neoadjuvant Chemotherapy Combined with Immunotherapy for Esophageal Squamous Cell Carcinoma via Enhanced CT Radiomics Combined with Clinical Features.2025Technology in cancer research & treatmentFree full text
  8. The predictive role of PNI and NRS2002 for postoperative pulmonary complications in ESCC patients undergoing neoadjuvant chemoimmunotherapy followed by McKeown esophagectomy: a retrospective cohort study.2025World journal of surgical oncologyFree full text
  9. Consensus Clustering Analysis Based on Enhanced-CT Radiomic Features: Esophageal Squamous Cell Carcinoma patients' 3-Year Progression-Free Survival.2024Academic radiology
  10. Development of a Specific Aptamer-Modified Nano-System to Treat Esophageal Squamous Cell Carcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  11. Examining the relationship between preoperative nutritional and symptom assessment and postoperative atrial fibrillation in esophageal squamous cell carcinoma patients: a retrospective cohort study.2024BMC surgeryFree full text
  12. hOGG1: A novel mediator in nitrosamine-induced esophageal tumorigenesis.2024Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  13. FAP positive cancer-associated fibroblasts promote tumor progression and radioresistance in esophageal squamous cell carcinoma by transferring exosomal lncRNA AFAP1-AS1.2024Molecular carcinogenesis
  14. Single-Cell Transcriptomics Reveals STAT1 Drives LHPP Downregulation in Esophageal Squamous Cell Carcinoma Progression.2024Technology in cancer research & treatmentFree full text
  15. A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker.2023Canadian journal of gastroenterology & hepatologyFree full text
  16. Single-cell transcriptomics reveals heterogeneity in esophageal squamous epithelial cells and constructs models for predicting patient prognosis and immunotherapy.2023Frontiers in immunologyFree full text
  17. LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma.2021Cell death & diseaseFree full text
  18. ZFX promotes tumorigenesis and confers chemotherapy resistance in esophageal squamous cell carcinoma.2021Clinics and research in hepatology and gastroenterology
  19. Self-assembled RNA nanocarrier-mediated chemotherapy combined with molecular targeting in the treatment of esophageal squamous cell carcinoma.2021Journal of nanobiotechnologyFree full text
  20. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.2021Radiation oncology (London, England)Free full text
All its trials on ClinicalTrials.gov, any status6
  1. Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of EsophagusStatus unknownNCT03585530Lead sponsorPhase 2Start 2018-09
  2. Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03600831Lead sponsorPhase 2/Phase 3Start 2018-08
  3. Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning FeaturesCompletedNCT07181850Lead (inferred)Start 2019-01
  4. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  5. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  6. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)10
  1. Construction of a egg yolk lipid-based co-delivery nano-drug system targeting PDPN and its in vitro anti-esophageal squamous cell carcinoma effects2025DOAJ (DOAJ: Directory of Open Access Journals)article
  2. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physicsarticle
  3. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncologyretraction
  4. Comparing toripalimab combined with chemoradiotherapy versus chemoradiotherapy alone for locally advanced esophageal squamous cell carcinoma: A multicenter, open-label, randomized phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  5. Retrospective study of continued immunotherapy in patients with advanced esophageal squamous cell carcinoma after progression on first-line immunotherapy combination chemotherapy.2024Journal of Clinical Oncologyconference-abstract
  6. 132TiP Dose escalation of chemoradiotherapy in locally advanced esophageal squamous cell carcinoma based on positron emission tomography response: A phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)2022Annals of Oncologyarticle
  7. Cholinergic signals promote esophageal squamous cell carcinoma metastasis by activating EGFR/AKT signaling pathway2022Research Squarepreprint
  8. Cholinergic signals promote esophageal squamous cell carcinoma metastasis by activating EGFR/AKT signaling pathway2022Research Squarepreprint
  9. Cholinergic signals promote esophageal squamous cell carcinoma metastasis by activating EGFR/AKT signaling pathway2022Research Squarepreprint
  10. ASO Visual Abstract: Additional esophagectomy following noncurative endoscopic resection for early esophageal squamous cell carcinoma: a multicenter retrospective study2021Annals of Surgical Oncologyarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 6 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 0020232024: 2220242025: 002025

1 hospital in Huai'an for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapy & targeted drugsImaging, AI & early detectionRecurrence & prognosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 13 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 2220222023: 2220232024: 3320242025: 112025

1 hospital in Huai'an for stomach cancer211 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseNutrition & recoveryImmunotherapy & targeted drugs
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led13
  1. Serum pyruvate and lactate predict immunotherapy efficacy in advanced gastric cancer: a prospective biomarker study.2025Frontiers in immunologyFree full text
  2. Ligation-assisted endoscopic full-thickness resection combined with preloaded sutures for tiny mesenchymal tumors of the gastric fundus.2024EndoscopyFree full text
  3. Noxa inhibits oncogenesis through ZNF519 in gastric cancer and is suppressed by hsa-miR-200b-3p.2024Scientific reportsFree full text
  4. Application of the Left Lateral Decubitus Position in Laparoscopic Right Posterior Lobectomy.2024Surgical laparoscopy, endoscopy & percutaneous techniques
  5. Metastatic breast carcinoma and Krukenberg tumor from signet-ring cell gastric cancer.2023Asian journal of surgery
  6. Simple Scoring Model Based on Enhanced CT in Preoperative Prediction of Biological Risk of Gastrointestinal Stromal Tumor.2023Technology in cancer research & treatmentFree full text
  7. Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures.2022Immunity, inflammation and diseaseFree full text
  8. Knockdown of mediator complex subunit 27 suppresses gastric cancer cell metastasis and angiogenesis via Wnt/β-catenin pathway.2022Tissue & cell
  9. MiRNA-621 exerts tumor suppressor function in gastric adenocarcinoma by targeting AURKA/GSK-3β pathway.2021Acta biochimica Polonica
  10. RNF168 promotes RHOC degradation by ubiquitination to restrain gastric cancer progression via decreasing HDAC1 expression.2021Biochemical and biophysical research communications
  11. DLX6 Antisense RNA 1 Modulates Glucose Metabolism and Cell Growth in Gastric Cancer by Targeting microRNA-4290.2021Digestive diseases and sciences
  12. Integrated bioinformatics analysis for differentially expressed genes and signaling pathways identification in gastric cancer.2021International journal of medical sciencesFree full text
  13. NUPR1 participates in YAP-mediate gastric cancer malignancy and drug resistance via AKT and p21 activation.2021The Journal of pharmacy and pharmacology
Chinese-language papers (not in the count)1
  1. [Preliminary exploration of modified side overlap with fundoplication by Yamashita (mSOFY) anastomosis technique in laparoscopic proximal gastrectomy].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status2
  1. Safety and Efficacy of γδ T Cell Against Gastric CancerStatus unknownNCT02585908Study sitePhase 1/Phase 2Start 2019-12
  2. Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.Status unknownNCT02602249Study sitePhase 1Start 2017-10

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 19 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.08%.

Papers led
19
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 5520232024: 2220242025: 442025

1 hospital in Huai'an for lung cancer251 hospitals in China for lung cancer

No open trial on lung cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineRadiation oncologyMedical oncologyGastroenterology / hepatology
Papers it led19
  1. RFWD3 Knockdown Inhibits Cancer Cell Proliferation, Migration, and Invasion while Promoting Apoptosis of Non-Small Cell Lung Cancer Cells.2025Archivum immunologiae et therapiae experimentalis
  2. Immunological biomarkers and gene signatures predictive of radiotherapy resistance in non-small cell lung cancer.2025Frontiers in immunologyFree full text
  3. Predicting Gene Comutation of EGFR and TP53 by Radiomics and Deep Learning in Patients With Lung Adenocarcinomas.2025Journal of thoracic imagingFree full text
  4. Retrospective comparative study of thoracoscopic lobectomy vs. segmentectomy: Enhancing recovery and lung function in early-stage non-small cell lung cancer.2025MedicineFree full text
  5. CENPF Upregulation is Associated with Immunosuppressive Status and Poor Clinical Outcomes in Lung Adenocarcinoma Validated by qRT-PCR.2024Combinatorial chemistry & high throughput screening
  6. Predicting visceral pleural invasion in lung adenocarcinoma presenting as part-solid density utilizing a nomogram model combined with radiomics and clinical features.2024Thoracic cancerFree full text
  7. Identification of a novel RSRC1-ALK (R6: A20) fusion using next-generation sequencing technique.2023Cancer genetics
  8. Identification of Immune Infiltration and Prognostic Biomarkers in Small Cell Lung Cancer Based on Bioinformatic Methods from 3 Studies.2023Combinatorial chemistry & high throughput screening
  9. Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway.2023Drug development research
  10. High‑risk pathological subtype associated FAM83A‑AS1 promotes malignancy and glycolysis of lung adenocarcinoma via miR‑202‑3p/HK2 axis.2023Oncology reportsFree full text
  11. Comparison and fusion prediction model for lung adenocarcinoma with micropapillary and solid pattern using clinicoradiographic, radiomics and deep learning features.2023Scientific reportsFree full text
  12. Developing and validating a prediction model for in-hospital mortality in patients with ventilator-associated pneumonia in the ICU.2022Annals of palliative medicine
  13. CKS2 Promotes the Growth in Non-Small-Cell Lung Cancer by Downregulating Cyclin-Dependent Kinase Inhibitor.2022Pathobiology : journal of immunopathology, molecular and cellular biology
  14. SOX2 como posible biomarcador pronóstico y diana molecular en el cáncer de pulmón: metaanálisis.2022Revista clinica espanola
  15. Ultrasound-Guided Thoracic Paravertebral Nerve Block on Postoperative Pain, Quality of Life, and Recovery in Patients with Non-Small-Cell Lung Cancer.2021BioMed research internationalFree full text
  16. RNF168 promotes RHOC degradation by ubiquitination to restrain gastric cancer progression via decreasing HDAC1 expression.2021Biochemical and biophysical research communications
  17. MicroRNA miR-19b-3p mediated G protein γ subunit 7 (GNG7) loss contributes lung adenocarcinoma progression through activating Hedgehog signaling.2021BioengineeredFree full text
  18. Integrative Molecular Analyses of an Individual Transcription Factor-Based Genomic Model for Lung Cancer Prognosis.2021Disease markersFree full text
  19. Prediction efficacy of feature classification of solitary pulmonary nodules based on CT radiomics.2021European journal of radiology
Chinese-language papers (not in the count)1
  1. [Clinical value of a differentiation prediction model for invasive lung adenocarcinoma].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status3
  1. Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung CancerCompletedNCT04952597Study sitePhase 2Start 2021-07
  2. A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT04325763Study sitePhase 3Start 2020-05
  3. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruitingNCT03974022Study sitePhase 1/Phase 2Start 2019-07

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 5 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.07%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 222025

1 hospital in Huai'an for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryRadiation oncology
Papers it led5
  1. Causes of death among patients with primary malignant brain tumors in the US from 2000 to 2021.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. Targeted therapy for glioblastoma utilizing hyaluronic acid-engineered liposomes for adriamycin delivery.2025Nanotechnology
  3. DBX2 Promotes Glioblastoma Cell Proliferation by Regulating REST Expression.2022Current pharmaceutical biotechnology
  4. ITPRIP promotes glioma progression by linking MYL9 to DAPK1 inhibition.2021Cellular signalling
  5. Positioning error analysis of the fraxion localization system in the intracranial stereotactic radiotherapy of tumors.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Huai'an for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Knockdown of otubain 2 inhibits liver cancer cell growth by suppressing NF-κB signaling.2020The Kaohsiung journal of medical sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 3 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 1.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Huai'an for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 1120232024: 1120242025: 002025

1 hospital in Huai'an for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led6
  1. Nanoparticles-encapsulated doxorubicin alleviates drug resistance of osteosarcoma via inducing ferroptosis.2024Nanotoxicology
  2. ALOX5AP suppresses osteosarcoma progression via Wnt/β-catenin/EMT pathway and associates with clinical prognosis and immune infiltration.2023Journal of orthopaedic surgery and researchFree full text
  3. Circular RNA circ_0002137 regulated the progression of osteosarcoma through regulating miR-433-3p/ IGF1R axis.2022Journal of cellular and molecular medicineFree full text
  4. Expression level of PLAC1 in osteosarcoma patients and its regulatory effect on the development of osteosarcoma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  5. The circular RNA circCRIM1 inhibits osteosarcoma progression through sponging miR-513.2021Mammalian genome : official journal of the International Mammalian Genome Society
  6. Depletion of circRNA circ_CDK14 inhibits osteosarcoma progression by regulating the miR-520a-3p/GAB1 axis.2021Neoplasma
Earlier papers (2016–2020)12
  1. MicroR-542-3p can mediate ILK and further inhibit cell proliferation, migration and invasion in osteosarcoma cells.2019Aging
  2. SP1-mediated upregulation of lncRNA ILF3-AS1 functions a ceRNA for miR-212 to contribute to osteosarcoma progression via modulation of SOX5.2019Biochemical and biophysical research communications
  3. Elevated long noncoding RNA HAGLROS expression correlates with clinical progression and prognosis in osteosarcoma.2019European review for medical and pharmacological sciences
  4. Long noncoding RNA OIP5-AS1 accelerates CDK14 expression to promote osteosarcoma tumorigenesis via targeting miR-223.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  5. Logistic regression analysis for the identification of the metastasis-associated signaling pathways of osteosarcoma.2018International journal of molecular medicine
  6. LINC00968 functions as an oncogene in osteosarcoma by activating the PI3K/AKT/mTOR signaling.2018Journal of cellular physiology
  7. miR‑590‑5p suppresses osteosarcoma cell proliferation and invasion via targeting KLF5.2018Molecular medicine reports
  8. Identification of Key Gene Modules in Human Osteosarcoma by Co-Expression Analysis Weighted Gene Co-Expression Network Analysis (WGCNA).2017Journal of cellular biochemistry
  9. Folic acid-tagged titanium dioxide nanoparticles for enhanced anticancer effect in osteosarcoma cells.2017Materials science & engineering. C, Materials for biological applications
  10. Assessment of GSK1904529A as a promising anti-osteosarcoma agent.2017Oncotarget
  11. RBEL1 is required for osteosarcoma cell proliferation via inhibiting retinoblastoma 1.2016Molecular medicine reports
  12. Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab.2016Orthopaedic surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

1 hospital in Huai'an for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Huai'an for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 332025

1 hospital in Huai'an for multiple myeloma175 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

1 hospital in Huai'an for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesCAR-T & cell therapyStem cell transplantPhiladelphia chromosome & genetics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 11 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
11
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 4420242025: 552025

1 hospital in Huai'an for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06566807

    Age 18 years to Not stated (registered criteria)

    Led by Huai'an First People's HospitalHuai'an

  2. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncologyENT / head & neck surgery
Papers it led11
  1. Prognostic significance of CDK1 expression in diffuse large B-Cell lymphoma.2025BMC cancerFree full text
  2. Spautin-1 inhibits the growth of diffuse large B-cell lymphoma by inducing mitochondrial damage-mediated PANoptosis and anti-tumor immunity.2025Cancer immunology, immunotherapy : CIIFree full text
  3. Global, regional, and national burden of Hodgkin lymphoma, 1990-2021, and predictions for 2050: an analysis of the global burden of disease study 2021.2025Expert review of hematology
  4. CDK1 inhibitor RO-3306 enhances BTKi potency in diffuse large B-cell lymphoma by suppressing JAK2/STAT3 signaling.2025International journal of biological macromolecules
  5. Cathepsins effect on diffuse large B cell lymphoma risk: A Mendelian randomization study.2025MedicineFree full text
  6. Development and validation of prognostic models based on 18F-FDG PET radiomics, metabolic parameters, and clinical factors for elderly DLBCL patients.2024Annals of hematology
  7. Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  8. The association of COVID-19 with diffuse large B-cell lymphoma: a Mendelian randomization study.2024International journal of environmental health research
  9. The current status and future trends of BTK inhibitor for diffuse large B cell lymphoma.2024Pharmacological research
  10. The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization study.2023Frontiers in immunologyFree full text
  11. ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma.2021Current cancer drug targets
Chinese-language papers (not in the count)1
  1. [The relationship between Epstein-Barr virus and extranodal NK/T-cell lymphoma, nasal type].2024Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
All its trials on ClinicalTrials.gov, any status7
  1. Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone LymphomaRecruitingNCT06566807Lead sponsorPhase 2Start 2024-08
  2. A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLStatus unknownNCT06445257Lead sponsorN/AStart 2023-09
  3. ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingNCT06378138Study sitePhase 2/Phase 3Start 2024-05
  4. Obinutuzumab in Chinese Real-world Patients With iNHLStatus unknownNCT05968001Study siteStart 2023-07
  5. Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLLStatus unknownNCT02546739Study sitePhase 1Start 2021-03
  6. A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)Status unknownNCT04398953Study sitePhase 2Start 2020-07
  7. Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell LymphomaStatus unknownNCT02879526Study sitePhase 2Start 2016-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 5 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 222025

1 hospital in Huai'an for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    Phase
    N/A
    Started
    2021-09
    Posted
    Registry
    NCT04995159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

淮安市第一人民医院

Huai'an First People's Hospital

淮安

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Huaian First People's Hospital; Affiliated Huai'an First People's Hospital; Huai'an first people's hospital; Huai'an No.1 People's Hospital; Huaian First People’s Hospital

Suggest a correctionDownload the data